CoChat

Involvement of glucagon‐like peptide‐1 in the glucose‐lowering effect of metformin

Bahne, Emilie, Hansen, Morten, Brønden, Andreas, Sonne, David P., Vilsbøll, Tina, Knop, Filip K. · 2016 · Diabetes, Obesity and Metabolism
Cited by 72

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Metformin is an oral antihyperglycaemic drug used in the first‐line treatment of type 2 diabetes. Metformin's classic and most well‐known blood glucose‐lowering mechanisms include reduction of hepatic gluconeogenesis and increased peripheral insulin sensitivity. Interestingly, intravenously administered metformin is ineffective and recently, metformin was shown to increase plasma concentrations of the glucose‐lowering gut incretin hormone glucagon‐like peptide‐1 ( GLP ‐1), which may contribute to metformin's glucose‐lowering effect in patients with type 2 diabetes. The mechanisms behind metformin‐induced increments in GLP ‐1 levels remain unknown, but it has been hypothesized that metformin stimulates GLP ‐1 secretion directly and/or indirectly and that metformin prolongs the half‐life of GLP ‐1. Also, it has been suggested that metformin may potentiate the glucose‐lowering effects of GLP ‐1 by increasing target tissue sensitivity to GLP ‐1. The present article critically reviews the possible mechanisms by which metformin may affect GLP ‐1 levels and sensitivity and discusses whether such alterations may constitute important and clinically relevant glucose‐lowering actions of metformin.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12697

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 72

Metadata

Authors
Bahne, E., Hansen, M., Brønden, A., Sonne, D. P., Vilsbøll, T., & Knop, F. K.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2016-07-13
Volume
18
Issue
10
Pages
955-961
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2414767657
Cited by
72
References
17
FWCI
7.22
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.